CPI-444 是一種有效的選擇性 A2A 受體 (A2AR) 拮抗劑,誘導(dǎo)抗腫瘤反應(yīng)。
IN VIVO: CPI-444 treatment resulted in a similar inhibition of tumor growth in the B16F10 melanoma (100 mg/kg) and RENCA renal cell cancer syngeneic models (10 mg/kg). It enhances T-cell activation in both the periphery and tumor microenvironment[1].
上海晴宜生物科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!